AbbVie
AbbVie is seeking a Scientist I or II to support the development of clinical-stage targeted Lipid Nanoparticle (tLNP) assets through hands-on laboratory experimentation and formulation optimization. This role involves designing experiments, characterizing drug products, and collaborating with cross-functional teams to advance tLNP programs from early research to clinical enablement. Candidates will utilize analytical techniques and statistical tools to ensure the robust development and stability of innovative drug delivery systems.
Headquarters
North Chicago, Illinois, United States
Company Size
10001+ employees
Founded
2013
AbbVie is a global, research-driven biopharmaceutical company that was spun off from Abbott Laboratories in 2013. It develops and commercializes specialty medicines across immunology, oncology, neuroscience, eye care and virology — with Humira historically its flagship product — and has broadened its portfolio through acquisitions (notably Allergan) and strategic collaborations. AbbVie emphasizes a robust R&D pipeline, targeted therapies, and global commercial and manufacturing capabilities. The company focuses on delivering long-term treatment options for complex, chronic and serious diseases.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for AbbVie.
AbbVie didn’t post a salary, so this is our estimate from similar listings.
28% below the average for this role
Senior Scientist I, tLNP Formulation
AbbVie
Associate Scientist I, Formulation and Process Development
AbbVie
Scientist I, Formulation and Process Development
AbbVie
Scientist I, Formulation and Process Development
AbbVie
Scientist, mRNA Formulation
GSK plc
Scientist I, Formulation and Process Development
AbbVie